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Original Article
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Background: Long-term continuous positive airway pressure (CPAP) usage varies between individuals. 
It would be of value to be able to identify those who are likely to benefit from CPAP (and use it long term), 
versus those who would not, and might therefore benefit from additional help early on. First, we explored 
whether baseline characteristics predicted CPAP usage in minimally symptomatic obstructive sleep apnoea 
(OSA) patients, a group who would be expected to have low usage. Second, we explored if early CPAP usage 
was predictive of longer-term usage, as has been shown in more symptomatic OSA patients.
Methods: The MOSAIC trial was a multi-centre randomised controlled trial where minimally symptomatic 
OSA patients were randomised to CPAP, or standard care, for 6 months. Here we have studied only those 
patients randomised to CPAP treatment. Baseline characteristics including symptoms, questionnaires 
[including the Epworth sleepiness score (ESS)] and sleep study parameters were recorded. CPAP usage was 
recorded at 2–4 weeks after initiation and after 6 months. The correlation and association between baseline 
characteristics and 6 months CPAP usage was assessed, as was the correlation between 2 and 4 weeks CPAP 
usage and 6 months CPAP usage.
Results: One hundred and ninety-five patients randomised to CPAP therapy had median [interquartile range 
(IQR)] CPAP usage of 2:49 (0:44, 5:13) h:min/night (h/n) at the 2–4 weeks visit, and 2:17 (0:08, 4:54) h/n at the  
6 months follow-up visit. Only male gender was associated with increased long-term CPAP use (male usage 2:56 h/n,  
female 1:57 h/n; P=0.02). There was a moderate correlation between the usage of CPAP at 2–4 weeks and  
6 months, with about 50% of the variability in long-term use being predicted by the short-term use.
Conclusions: In patients with minimally symptomatic OSA, our study has shown that male gender (and 
not OSA severity or symptom burden) is associated with increased long-term use of CPAP at 6 months. 
Although, in general, early patterns of CPAP usage predicted longer term use, there are patients in whom 
this is not the case, and patients with low initial usage may need to extend their CPAP trial before a decision 
about longer-term use is made.
Keywords: Obstructive sleep apnoea (OSA); continuous positive airway pressure (CPAP); patient compliance
Submitted Nov 05, 2015. Accepted for publication Nov 25, 2015.
doi: 10.3978/j.issn.2072-1439.2016.01.54
View this article at: http://dx.doi.org/10.3978/j.issn.2072-1439.2016.01.54
277Journal of Thoracic Disease, Vol 8, No 2 February 2016
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016;8(2):276-281www.jthoracdis.com
Introduction
Continuous positive airway pressure (CPAP) usage is 
variable in obstructive sleep apnoea (OSA). Large scale 
trials of CPAP for patients recruited based on cardiovascular 
risk, who are generally less sleepy, have shown particularly 
low usage (1). This may be due to patients not perceiving 
benefit from CPAP, as they are usually not very sleepy.
In a previous study, severity of OSA, measured by the 
oxygen desaturation index (ODI) >4%, was predictive 
of CPAP compliance (2). This work looked at patients 
with OSA from the sleep clinic who mainly had classical 
symptoms of excessive daytime somnolence (EDS). It is 
interesting to note that in this previous paper, symptoms, 
particularly as measured by the Epworth sleepiness score 
(ESS), were not predictive of long-term CPAP compliance.
In patients with OSA and EDS, CPAP treatment not only 
improves symptoms, but it also reduces blood pressure (3). 
However, a recent meta-analysis (4), in minimally 
symptomatic patients, also showed that CPAP treatment 
did, on average, reduce daytime somnolence compared 
to controls, but only improved diastolic blood pressure in 
patients who used CPAP for ≥4 h/night. Predicting long-term 
CPAP usage in minimally symptomatic OSA patients would 
be useful to identify patients most likely to benefit from 
therapy.
In this current study: first, we aimed to see if the 
relationship between ODI and CPAP usage found in our 
earlier work could be verified in a population of minimally 
symptomatic patients and whether any other baseline 
characteristics predicted long-term CPAP usage; second, we 
aimed to see if early patterns of CPAP usage were predictive 
of usage at 6 months, to test the validity of using only a 
short trial of CPAP to determine longer-term use.
Methods
The MOSAIC trial
The MOSAIC trial was a multicentre randomised, parallel, 
6-month controlled trial that was conducted between 
May 2006 and February 2010. The trial was approved 
by the ethics committees of all the centres (REC No: 
05/Q1604/159) and registered (ISRCTN 34164388).
Patients were randomized to 6 months of CPAP, or 
standard care, if they had an ODI of >7.5 events/h due to 
OSA on a baseline sleep study, but the enrolling physician 
and patient felt they had insufficient daytime symptoms 
to mandate CPAP treatment. The full protocol has been 
published previously (5).
In this current study we assessed only the patients 
randomised to CPAP in the MOSAIC trial. First, we 
investigated the association of baseline characteristics with 
6 months CPAP usage. Second, we explored the correlation 
between 2 and 4 weeks usage of CPAP and 6 months usage.
Baseline characteristics
Patient demographics, symptoms, ODI, ESS, Sleep Apnoea 
Quality of Life Index (SAQLI), short form-36 physical 
(SF-36 PCS) and mental (SF-36 MCS) summary scores, and 
maintenance of wakefulness test equivalent (OSLER test) (6) 
were assessed. After enrolment but before randomisation, 
overnight pulse oximetry was repeated with the same oximeters 
(Minolta) across all centres for uniformity of trial ODI.
CPAP usage
Patients were invited to follow-up between 2 and 4 weeks, 
and 6 months after randomisation. Data was analysed 
regardless of exactly when they attended these trial 
appointments. CPAP usage was assessed at the 2–4 weeks 
and the 6 months visits. Study withdrawals were assigned 
0:00 h:min/night (h/n) in the analyses.
At 2–4 weeks follow-up, all nights were analysed where 
available and a mean nightly usage calculated.
We defined long-term usage at 6 months follow-up in 
two ways. In method 1, all nights between the 2–4 weeks 
and 6 months follow-up were analysed when available, and 
a mean 6-month usage calculated. In method 2, the average 
CPAP usage was recorded over the shorter period of 1 week 
prior to the 6 months follow-up.
Method 2 was thought most likely to reflect longer-term 
CPAP usage beyond 6 months. Method 2 however, runs the 
risk of not necessarily being fully representative due to short 
term differences such as a holiday, or an upper respiratory 
tract infection.
Patient willingness to continue CPAP
To explore a different aspect of CPAP acceptance in this 
minimally symptomatic group, patients were asked at the 
6 months follow-up whether they were prepared to continue 
CPAP beyond the 6 months trial period. Study withdrawals 
and those with missing data were assumed to have been 
unwilling to continue CPAP.
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Statistical analysis
Statistical analysis was performed using IBM SPSS 
software, version 20. Baseline characteristics were compared 
to 6 months usage data using t-tests or one way ANOVA 
(categorical variables), and univariable linear regression 
(continuous variables) with assumption of normality of the 
samples means due to the large sample size (central limits 
theorem). Correlation between variables was also assessed 
using Pearson’s correlation coefficient.
Multivariable regression was performed for all baseline 
characteristics as the independent predictors and with the 
6 months CPAP usage as the dependant variable in a 
stepwise backwards model (variables with P>0.10 removed) 
and separately with a stepwise forward model (variables with 
P<0.05 included).
Separately 2–4 weeks follow-up CPAP usage was 
compared to 6 months CPAP usage data with Pearson’s 
correlation.
Results
One hundred and ninety-five patients were randomised 
to receive CPAP during the MOSAIC trial. The baseline 
characteristics for these patients are shown in Table 1.
One hundred and eighty-eight patients attended 
2–4 weeks follow-up and median time to follow-up was 21 days 
(interquartile range or IQR 15 to 28), 183 patients attended 
their 6 months follow-up, median time to follow-up was 
195 days (IQR 182 to 210).
Usage
The median (IQR) of the mean daily CPAP usage was 2:49 (0:44, 
5:13) h/n at the 2–4 weeks visit. It was 2:17 (0:08, 4:54) h/n 
at the 6 months follow-up visit (method 1) and 2:12 (0:00, 
5:27) h/n in the week prior to 6 months follow-up visit 
(method 2). Forty (21%) patients had either stopped CPAP 
treatment at 6 months follow-up or did not attend follow-up.
Table 1 Baseline characteristics for male patients, female patients and all patients
Variable
Mean (SD), median (IQR) or number (%)
Male Female All patients
Number (%) 153 (78.5) 42 (21.5) 195 (100.0)
Age, median years [IQR] 58 [51, 63] 60 [51, 65] 59 [51, 63]
Ethnicity, number white (%) 148 (96.7) 40 (95.2) 188 (96.4)
BMI, median kg/m2 (IQR) 31.1 (28.7, 33.8) 30.9 (27.6, 36.9) 31.1 (28.0, 34.4)
Smoking status, number (%)
Current 15 (9.8) 2 (4.8) 17 (8.7)
Ex-smoker 87 (56.9) 15 (35.7) 102 (52.3)
Never smoker 51 (33.3) 25 (59.5) 76 (39.0)
Reported snoring, number yes (%) 149 (97.4) 41 (97.6) 190 (97.4)
Reported apneas, number yes (%) 116 (75.8) 26 (61.9) 142 (72.8)
Reported choking, number yes (%) 52 (34.0) 14 (33.3) 66 (33.8)
Reported nocturia, number yes (%) 85 (55.6) 29 (69.0) 114 (58.5)
ODI, median (IQR) 10.3 (4.6, 18.7) 9.6 (5.1, 14.7) 10.2 (4.7, 17.5)
ESS, median [IQR] 8 [4, 11] 9 [2, 12] 8 [4, 11]
SAQLI, median (IQR) 4.9 (4.1, 5.9) 4.9 (3.7, 5.8) 4.9 (4.0, 5.9)
SF-36 physical summary, median (IQR) 45.3 (33.6, 51.8) 39.1 (33.1, 49.8) 44.8 (33.6, 51.6)
SF- 36 mental summary, median (IQR) 50.9 (41.1, 57.0) 48.2 (39.6, 55.9) 50.5 (40.5, 56.6)
OSLER, median seconds (IQR) 2,400 (1,799, 2,400) 2,400 (1,169, 2,400) 2,400 (1,680, 2,400)
SD, standard deviation; IQR, interquartile range; BMI, body mass index; ODI, oxygen desaturation index; ESS, Epworth sleepiness 
score; SAQLI, Sleep Apnoea Quality of Life Index; SF-36, short form-36; OSLER, Oxford sleep latency test.
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Table 3 Comparison of CPAP usage and categorical variables
Categorical variables Mean (SD) N 95% CI P
Snoring −0:21, 4:00 0.06
Yes 2:40 (2:27) 190
No 4:30 (1:37) 5
Apnoeas −1:19, 0:16 0.19
Yes 2:51 (2:26) 142
No 2:20 (2:29) 51
Choking −0:05, 1:22 0.08
Yes 2:18 (2:21) 66
No 2:56 (2:28) 129
Nocturia −0:30, 0:55 0.56
Yes 2:37 (2:31) 114
No 2:50 (2:22) 79
Gender −1:49, −0:09 0.02*
Male 2:56 (2:29) 153
Female 1:57 (2:11) 42
Ethnicity −2:29, 1:14 0.50
White 2:45 (2:28) 188
Non-White 2:07 (1:55) 7
Smoking status / 0.26
Never smoker 2:52 (2:27) 76
Ex-smoker 2:46 (2:28) 102
Current smoker 1:48 (2:14) 17
For categorical variables the differences in mean CPAP 
usage at 6 months (method 1) were compared using unpaired 
t-tests. For smoking status differences between groups in 
mean CPAP usage at 6 months (method 1) were compared 
with a one way ANOVA. *, P<0.05. CPAP, continuous positive 
airway pressure; SD, standard deviation; 95% CI, 95% 
confidence intervals of difference in means between groups.
Table 2 Comparison of CPAP usage and continuous variables
Continuous 
variables
B (unstandardized), 
h/night
Pearson’s 
correlation 
coefficient
P
Age (years) −0.01 −0.04 0.59
BMI (kg/m2) −0.03 −0.06 0.37
ODI (events/hour) 0.007 0.04 0.59
ESS −0.04 −0.06 0.38
SAQLI 0.14 0.07 0.37
SF-36 physical 
summary
0.004 0.02 0.79
SF-36 mental 
summary
0.02 0.07 0.32
OSLER (s) 0.000 −0.05 0.53
The association between continuous variables and mean 
CPAP usage at 6 months (method 1) was assessed using 
univariable linear regression (B) and correlation was assessed 
using Pearson’s correlation coefficient. CPAP, continuous 
positive airway pressure; BMI, body mass index; ODI, oxygen 
desaturation index >4%; ESS, Epworth sleepiness score; 
SAQLI, Sleep Apnoea Quality of Life Index; SF-36, short form 
36; OSLER, Oxford sleep latency test.
Baseline characteristics and 6 months CPAP usage (method 1)
Mean CPAP usage at 6 months was significantly greater in 
male participants [mean daily male usage 2:56 h/n, female 
1:57 h/n; 95% confidence interval (CI) −1:49, −0:09 h/n, 
P=0.02]. For all other categorical variables there were no 
other significant effects on CPAP usage. None of the baseline 
characteristics that were continuous variables were significantly 
associated with CPAP usage at 6 months (Tables 2,3).
Using a stepwise backwards multivariable linear 
regression, male gender (unstandardized B =1:02 h/n, 
P=0.02) was associated with increased CPAP usage at 
6 months follow-up. In stepwise forwards multivariable 
linear regression male gender remained the only variable 
significantly associated with CPAP usage at 6 months. In 
both models gender only explained a small amount of the 
variance in CPAP usage (r2=0.03).
Baseline characteristics and 6 months CPAP usage (method 2)
In method 2 analyses, using only this last week of usage 
data, body mass index (BMI) was associated with increased 
long-term CPAP use (unstandardized B =−0:04 h/n per 
1 kg/m2 increase in BMI, r=−0.15, P=0.04) and male gender 
was associated with increased long-term CPAP use (male mean 
usage =3:02 h/n, female =1:56 h/n, P=0.01). No other baseline 
characteristics were significantly associated with long-term 
CPAP usage. Forwards multivariable analysis selected gender 
(r2=0.03) and backwards multivariable analysis selected both 
gender and BMI (r2=0.04), and suggested gender is dominant, 
but it still explained very little of the variance.
Two to four weeks usage and 6 months CPAP usage
Average hours of usage of CPAP at the 2–4 weeks follow-up 
was correlated with the average CPAP usage at 6 months 
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follow-up (method 1: r=0.77, r2=0.60, P<0.001, Figure 1. 
Method 2: r=0.65, r2=0.42, P<0.001).
Willingness to continue CPAP
One hundred and thirty-eight patients (70.8%) were 
prepared to continue CPAP beyond the 6 months follow-up. 
Despite declaring a preparedness to continue CPAP, 41 of these 
138 patients (30%) had used CPAP for less than 2:00 h/n.
Discussion
In patients with minimally symptomatic OSA the baseline 
characteristic most associated with increased CPAP usage 
at 6 months was male gender. There was only a moderate 
correlation between 2 and 4 weeks usage of CPAP and 
6 months usage; approximately 50% of the variance in 
long-term use being predicted by the short term use.
Gender differences have been reported previously, with 
higher CPAP usage in male patients (2,7,8). Only 42 of 
our participants were female, but our finding of higher 
male CPAP use supports a similar gender difference in 
CPAP usage for this minimally symptomatic group. This 
difference was not explained by sleep apnoea severity or 
differing symptoms between males and females. ODI and 
symptoms (ESS, SAQLI, SF-36) were similar in males 
and females at baseline, and did not show a significant 
contribution in the regression analysis.
Previously our unit conducted a large study of 639 patients 
initiated on CPAP (2). ODI was significantly correlated with 
CPAP adherence, but ESS was not. Elsewhere ESS alone was 
linked to CPAP usage (1), and in contrast Somiah et al. (9) 
found neither were correlated to CPAP usage. In this trial 
of patients with minimally symptomatic OSA we were 
not able to reproduce data showing either OSA severity 
(ODI) or ESS to be significant indicators of long-term 
CPAP usage.
The reasons why baseline ESS, ODI or other factors 
have not been consistently predictive of CPAP usage are not 
clear. It may be that we are simply not currently measuring 
at baseline the critical factors that determine CPAP usage; 
for example patient personality or other unmeasured 
consequences of sleep fragmentation. A second possibility 
is that a given ESS score is unlikely to indicate the same 
degree of sleepiness in different individuals, as people 
perceive the score differently. Supporting this concept, is the 
fact that the reduction in ESS, from baseline to 6 months, 
was associated with 6 months average CPAP usage (method 1; 
unstandardized B =0:14 h/n per 1 point increase in ESS, 
r=0.30, P<0.001), suggesting that the change in ESS 
following treatment may be more representative of the 
effects of OSA on an individual than the absolute value at 
baseline.
Patterns of CPAP usage have been shown to be established 
as early as the 4th night of CPAP use (10). We too have 
found in general that levels of CPAP usage are established 
early, with usage of CPAP at 2–4 weeks being moderately 
correlated to 6 months usage. However, a 2–4 weeks 
trial of CPAP for some is probably too short, as a 
significant minority (15 of 113 patients; 13%) who used 
CPAP <4 h/n at 2–4 weeks nonetheless went on to use 
CPAP for >4 h/n at the 6 months follow-up (method 1). 
Identifying low usage early may give clinicians an 
opportunity to improve usage, rather than being regarded 
as an indication of poor response.
Our analysis of usage in the last week prior to 6 months 
follow-up (method 2) was performed as this might be more 
representative of long-term usage, rather than the 6 months 
average following the first follow-up appointment (method 1). 
Usage was very similar in this last week compared to the 
whole 6 months average. In method 1, the median usage 
was 2:17 h/n, compared to 2:12 h/n in method 2 analysis 
(r=0.80, P<0.001). Both analyses showed that male gender 
was the baseline characteristic most strongly associated with 
increased longer-term CPAP usage.
Willingness to continue CPAP is often thought of as 
indicative of actual continuing CPAP usage. However, 
we found that many patients prepared to continue CPAP 
were in fact only using CPAP for 2 h or less a night (30%). 
Figure 1 Correlation between mean daily CPAP use at 2–4 weeks 
follow-up and 6 months follow-up (method 1, r=0.77, P<0.001). 
CPAP, continuous positive airway pressure; h/n, hours/night.
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Patients may only use CPAP on single nights prior to 
important events, such as driving long distances, and they 
may have significant personal benefit from CPAP below the 
current thresholds (non-evidence-based) currently used to 
define ‘adequate’ compliance (11).
Conclusions
Despite CPAP being of overall benefit in patients with 
minimally symptomatic OSA, this study has shown that 
male gender was associated with increased long-term CPAP 
usage at 6 months, and not ESS or ODI. Gender accounted 
for very little of the variation in CPAP usage at 6 months. 
Furthermore, this study supports research suggesting that 
patterns of CPAP usage are established early, although they 
can change in a clinically significant minority. One month 
may be too short a length of trial to determine patients 
likely to benefit from CPAP therapy in the longer term.
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